1. Yeasts isolated from Algerian infants's feces revealed a burden of Candida albicans species, non-albicans Candida species and Saccharomyces cerevisiae.
- Author
-
Seddik HA, Ceugniez A, Bendali F, Cudennec B, and Drider D
- Subjects
- Algeria, Antifungal Agents pharmacology, Candida drug effects, Candida isolation & purification, Candida physiology, Candida albicans drug effects, Candida albicans isolation & purification, Candida albicans physiology, Escherichia coli growth & development, Humans, Infant, Microbial Interactions, Saccharomyces cerevisiae drug effects, Saccharomyces cerevisiae isolation & purification, Saccharomyces cerevisiae physiology, Yeasts drug effects, Biodiversity, Feces microbiology, Yeasts isolation & purification, Yeasts physiology
- Abstract
This study aimed at showing the yeast diversity in feces of Algerian infants, aged between 1 and 24 months, hospitalized at Bejaia hospital (northeast side of the country). Thus, 20 colonies with yeast characteristics were isolated and identified using biochemical (ID32C Api system) and molecular (sequencing of ITS1-5.8S-ITS2 region) methods. Almost all colonies isolated (19 strains) were identified as Candida spp., with predominance of Candida albicans species, and one strain was identified as Saccharomyces cerevisiae. Screening of strains with inhibitory activities unveiled the potential of Candida parapsilosis P48L1 and Candida albicans P51L1 to inhibit the growth of Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 25923. Further studies performed with these two Candida strains revealed their susceptibility to clinically used antifungal compounds and were then characterized for their cytotoxicity and hemolytic properties. On the other hand, Saccharomyces cerevisiae P9L1 isolated as well in this study was shown to be devoid of antagonism but resulted safe and overall usable as probiotic.
- Published
- 2016
- Full Text
- View/download PDF